Lundbeck appoints new President and CEO

pharmafile | July 3, 2018 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing appointment, ludbeck, pharma 

The Danish pharmaceutical company Lundbeck has announced that the company’s Board of Directors have appointed Dr Deborah Dunshire as Lunbeck’s new president and CEO. Dr Dunshire will take up her new position on the 1 September 2018.

Having trained as a medical doctor in South Africa, Dr Dunshire brings a wealth of experience to the role. With more than 30 years of clinical, commercial and international management experience within the biotech and pharmaceutical industries, primarily in the fields of oncology and CNS, Dr Dunshire’s experience cover a vast area in bridging scientific and business expertise.

Her impressive resume includes a plethora of professional and executive experiences. Notably, previous roles include positions as President and CEO of XTuit Pharmaceuticals, Forum Pharmaceuticals and Millennium Pharmaceuticals.

“It is a great pleasure to announce that Deborah Dunshire will join Lundbeck as President and CEO,” said Lars Rasmussen, Chairman of Lundbeck’s Board of Directors. “She brings a wealth of highly successful R&D and commercial experiences including a robust knowledge and experience in neuroscience. She is a proven and highly passionate leader and has all the qualifications to take Lundbeck to the next level as a global leader within psychiatric and neurological disorders.”

Dr Dunshire, who plans to move to Denmark in connection with her new role, has lived in the United States since 1994 to which she migrated from South Africa. Following her graduation from the University of Witwatersrand in Johannesburg in 1985, Dr Dunshire practiced as a medical professional for two years before joining Sandoz in 1998.

“Lundbeck stands out in the industry as a global company with a great history of innovating in neuroscience, which is recognised to be one of the toughest research areas for the industry”, Dr Dunshire stated. “I am excited to bring my experience to help build an even stronger and brighter future for Lundbeck, patients, employees, partners and shareholders.”

Interim CEO Anders Götzche will resume his previous position of CFO when Dr Dunshire takes up her new position in September of this year.

Rasmussen added: “Anders has held the position as interim CEO since November 2017, and has together with the rest of management team done an excellent job in continuing the strong positive development that Lundbeck is having. The Board will like to express gratitude for a job well done and we look forward to see Lundbeck continuing the positive development under the new management team.”   

Related Content

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …


Novartis acquires Chinook Therapeutics for $3.5bn

Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based …

Latest content